2.67
3.61%
-0.10
After Hours:
2.63
-0.04
-1.50%
Cardiff Oncology Inc stock is traded at $2.67, with a volume of 551.92K.
It is down -3.61% in the last 24 hours and up +15.58% over the past month.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
See More
Previous Close:
$2.77
Open:
$2.77
24h Volume:
551.92K
Relative Volume:
1.01
Market Cap:
$122.43M
Revenue:
$488.00K
Net Income/Loss:
$-41.44M
P/E Ratio:
-2.9667
EPS:
-0.9
Net Cash Flow:
$-31.47M
1W Performance:
+3.49%
1M Performance:
+15.58%
6M Performance:
-50.00%
1Y Performance:
+92.09%
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-05-22 | Initiated | William Blair | Outperform |
Dec-08-21 | Initiated | Robert W. Baird | Outperform |
Aug-09-21 | Resumed | Maxim Group | Buy |
Oct-22-20 | Initiated | H.C. Wainwright | Buy |
Oct-08-20 | Initiated | Piper Sandler | Overweight |
Cardiff Oncology Inc Stock (CRDF) Latest News
KRAS Inhibitors Market: New Treatments Are Set to Change Cancer Care | DelveInsight - 新浪香港
Blair William & Co. IL Raises Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff City . . . The Doom Loop Club Stuck On Groundhog Day - Dai Sport
Investment Opportunities: Capitalizing on the Global Kras - openPR
Cardiff City need 'long-term strategy' after Erol Bulut exitRob Earnshaw - BBC.com
Tonight's Cardiff City news as 'stunned' club release statement and pundit picks 'fantastic' fit for job - Yahoo News UK
Trading Day Review: Cardiff Oncology Inc (CRDF) Loses Momentum, Closing at 2.58 - The Dwinnex
CRDF (Cardiff Oncology Inc) has impressive results - US Post News
Pompey Championship rival moves quickly to sort managerial mess after weekend sacking - Portsmouth News
Cardiff going from 'one crisis to another' - Yahoo Sport Australia
Next Cardiff City manager odds latest as Wales legend gatecrashes race - Yahoo News UK
The surprise Welsh names leading the field to become new Cardiff City manager - Nation.Cymru
Blackburn Rovers' rivals confirm third managerial casualty in the Championship - Lancashire Telegraph
Cardiff City candidate 'would love' to manage club after already rescuing Vincent Tan - Wales Online
Bluebirds give Bulut the bullet - MSN
Next Cardiff manager odds: Erol Bulut sacked after poor start - Sportinglife.com
SACKED! Cardiff axe Bulut - Tribal Football
Cardiff City sack Erol Bulut as club seek new manager - Wales Online
Next Cardiff Manager Odds: Who is favourite to replace Erol Bulut? - Oddschecker
Middlesbrough and Sunderland rivals looking for new boss after swift sacking call - Yahoo Eurosport UK
Cardiff City fire manager Erol Bulut - BBC
Cardiff Capital Region invests £45m in Ogi to boost digital connectivity - South Wales Argus
Market Watch Highlights: Cardiff Oncology Inc (CRDF) Ends on an Upturn Note at 2.53 - The Dwinnex
Cardiff Oncology Inc (CRDF)’s results reveal risk - US Post News
Tonight's Cardiff City news as Aaron Ramsey faces months out and Erol Bulut hits out over rumour - Wales Online
Thoroughbred Financial Services LLC Makes New Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
CEACAM5 Drugs Market Outlook: Rising Cancer Cases and Clinical Trials to Fuel Growth by 2034 | DelveInsight - PR Newswire UK
Ready to Jump After Recent Trade: Cardiff Oncology Inc (CRDF) - SETE News
CRDF’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Craig Hallum Initiates Coverage on Cardiff Oncology (NASDAQ:CRDF) - Defense World
Craig Hallum Initiates Coverage on Cardiff Oncology (NASDAQ:CRDF) - MarketBeat
Cardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Up 16.3% in August - MarketBeat
A better buy-in window may exist right now for Cardiff Oncology Inc (CRDF) - SETE News
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Assenagon Asset Management S.A. Buys 962,940 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Changing Trial Design When Stepping Up From Second-Line To First-Line Treatment - Clinical Leader
Head-To-Head Analysis: Agenus (NASDAQ:AGEN) versus Cardiff Oncology (NASDAQ:CRDF) - Defense World
Cardiff Oncology (STU:XE7C) Cash Flow from Investing : €33.30 Mil (TTM As of Jun. 2024) - GuruFocus.com
Cardiff Oncology to Present at Upcoming Investor Conferences in September - GuruFocus.com
Take off with Cardiff Oncology Inc (CRDF): Get ready for trading - SETE News
Vanguard Group Inc. Acquires 9,468 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Gaining Ground: Cardiff Oncology Inc (CRDF) Closes Lower at 2.18, Down -3.11 - The Dwinnex
The Cardiff Oncology Inc (CRDF) had a good session last reading, didn’t it? - US Post News
Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point (NASDAQ:CRDF) - Seeking Alpha
Cardiff Oncology Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Earnings call: Cardiff Oncology Q2 2024 update on CRDF-004 trial and finances - Investing.com
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q2 2024 Earnings Call Transcript - Insider Monkey
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript - Seeking Alpha
Balance Sheet Breakdown: Cardiff Oncology Inc (CRDF)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Cardiff Oncology Inc (CRDF) Q2 2024 Earnings: EPS Misses Estimat - GuruFocus.com
Cardiff Oncology: Q2 Earnings Snapshot - CTPost
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):